Pharmacokinetics of a cannabinoid-based therapy for canine disorders.
A phytocannabinoid-based medicine that is currently marketed for the treatment of spasticity and pain in multiple sclerosis patients in Spain was evaluated in dogs.
Related: Get our guide to CBD
Researchers administered the product sublingually to Beagle dogs. In one group, dogs received 3 sprays total and blood samples were collected at 12 intervals up to 24 h later. In another group, the dogs received 3 sprays daily for 14 days, and blood samples were collected for 24 h post final dose.
Maximal plasma concentrations of both Δ9-THC (Cmax = 18.5 ng/mL) and CBD (Cmax = 10.5 ng/mL) were achieved 2 h after administration in the single dose condition and at 1 h in the multiple dose treatment (Δ9-THC: Cmax = 24.5 ng/mL; CBD: Cmax = 15.2 ng/mL).
11hydroxy-Δ9-THC was almost undetected. A potential progressive accumulation of both CBD and Δ9-THC was detected following repeated exposure.
No changes were observed regarding any of the dog’s neurological status, body temperature, respiratory rate and hemodynamic parameters.
Read more by clicking on the link below:
Pharmacokinetics of a cannabinoid-based therapy for canine disorders.
